Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount Program

Description

{"description":" The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. \n\n P&T COMMITTEE MEETING: The following November 2025 newly approved drugs will be reviewed: \n\n a. Blujepa - Antibiotics - N/A \nb. Brekiya - Migraine Agents - N/A \nc. Dawnzera - Corticosteroids-Immune Modulators - Hereditary Angiodema Agents \nd. escitalopram - Antidepressants and Non-opioid Pain Syndrome Agents - Selective Serotonin Reuptake Inhibitors \ne. Exxua - Antidepressants and Non-opioid Pain Syndrome Agents - N/A \nf. Leqembi IQLIK - Alzheimers Agents - N/A \ng. ustekinumab-ttwe - Targeted Immunomodulatory Biologics - Interleukin 23 \nh. Wayrilz - Hematological Agents - Platelets \ni. Zurnai - Alcohol Deterrants-Narcotic Antagonists - Narcotic Antagonists \nj. Phyrago - Oncological Agents - Chronic Myelogenous Leukemia \nk. Inluriyo - Oncological Agents - N/A \nl. Enbumyst - Diuretics - N/A \n\n The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-25-Q-9404. \n\n \n\n Pre-quotation teleconference is on October 15, 2025. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2. \n"} Solicitation Number: HT9402-25-Q-9404 Type: Solicitation Base Type: Solicitation NAICS: 325412 Classification Code: 6505 Response Deadline: 2025-10-27T12:00:00-05:00 Office Address: AURORA, CO Place of Performance: San Antonio, Texas, 78230 POC: Keith Marasigan, keith.b.marasigan2.ctr@health.mil {"description":" The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. \n\n P&T COMMITTEE MEETING: The following November 2025 newly approved drugs will be reviewed: \n\n a. Blujepa - Antibiotics - N/A \nb. Brekiya - Migraine Agents - N/A \nc. Dawnzera - Corticosteroids-Immune Modulators - Hereditary Angiodema Agents \nd. escitalopram - Antidepressants and Non-opioid Pain Syndrome Agents - Selective Serotonin Reuptake Inhibitors \ne. Exxua - Antidepressants and Non-opioid Pain Syndrome Agents - N/A \nf. Leqembi IQLIK - Alzheimers Agents - N/A \ng. ustekinumab-ttwe - Targeted Immunomodulatory Biologics - Interleukin 23 \nh. Wayrilz - Hematological Agents - Platelets \ni. Zurnai - Alcohol Deterrants-Narcotic Antagonists - Narcotic Antagonists \nj. Phyrago - Oncological Agents - Chronic Myelogenous Leukemia \nk. Inluriyo - Oncological Agents - N/A \nl. Enbumyst - Diuretics - N/A \n\n The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-25-Q-9404. \n\n \n\n Pre-quotation teleconference is on October 15, 2025. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2. \n"}